Drug Profile
Research programme: amyotrophic lateral sclerosis therapeutics - ALS Therapy Development Institute/Regenesance
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Regenesance
- Developer ALS Therapy Development Institute; Regenesance
- Class
- Mechanism of Action Complement activation modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in Netherlands
- 16 Jul 2016 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
- 08 May 2012 Preclinical trials in Amyotrophic lateral sclerosis in Netherlands (unspecified route)